March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
March 20th 2023
Gene-Mediated Cytotoxic Immunotherapy Improves Survival in Newly Diagnosed GliomaNovember 22nd 2015
Adding adjuvant gene-mediated cytotoxic immunotherapy using aglatimagene besadenovec and valacyclovir to standard of care improves survival among patients undergoing surgery for newly diagnosed malignant glioma.
Markers Could Predict Risk of Brain Metastasis in Breast Cancer PatientsNovember 21st 2015
Serum matrix metalloproteinase 9 (MMP-9) and HER2 extra-cellular domain (HER2-ECD) might be predictive biomarkers for the metastasis of breast cancer to the brain, according to a case-control study.
Lomustine/Bevacizumab Fails to Improve Survival in Recurrent GlioblastomaNovember 20th 2015
Despite promising progression-free survival results, the combination of bevacizumab and lomustine for the treatment of first recurrence in glioblastoma did not improve overall survival, according to findings from the phase III EORTC-26101 trial.
Prognostic Factors for Germ Cell Tumor Patients With Brain MetastasesOctober 16th 2015
A recent study highlights factors that predict worse prognosis for patients with germ cell tumors whose cancer has spread to the brain, including the presence of liver or bone metastases, multiple brain metastases, and others.
Bevacizumab and Glioblastoma: The Ecstasy and the AgonyOctober 15th 2015
The absence of any effective combinatorial therapy in patients progressing on bevacizumab and evidence supporting both continuation and discontinuation of bevacizumab in this setting remain important areas for additional clinical trial evaluation in order to better guide our therapeutic decision making in the clinic.
Current and Emerging Treatments for Brain MetastasesApril 15th 2015
Conventional methods for treating brain metastasis, such as surgery, WBRT, and SRS, each compete with and complement one another. A plethora of recent studies have helped define and expand the utility of these tools.
Management of Brain Metastases in the Era of Targeted and Immunomodulatory TherapiesApril 15th 2015
Some targeted systemic therapies have demonstrated evidence of activity in the brain-specifically in melanoma, lung cancers, and breast cancers-and these agents warrant further study in clinical trials.
Treating Anaplastic Oligodendrogliomas and WHO Grade 2 Gliomas: PCV or Temozolomide? The Case for TemozolomideApril 15th 2015
There is no evidence that PCV is more effective than TMZ for the treatment of glioblastoma. However, there is unequivocal evidence that PCV is more toxic than TMZ.
Treating Anaplastic Oligodendrogliomas and WHO Grade 2 Gliomas: PCV or Temozolomide? The Case for PCVApril 15th 2015
In most cases, PCV chemotherapy will provide an edge in outcomes over TMZ for glioma patients, primarily because of the former regimen’s use of multiple drugs and their complementary interactions.